Grifols saw the highest growth of 0.82% in patent filings in May and 1.32% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.62% and grants by 1.32%. GlobalData’s DataBook provides a comprehensive analysis of Grifols‘s patent filings and grants. Buy the databook here.
Grifols has been focused on protecting inventions in European Patent Office(EPO) with 17 publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 34% filings and 15% grants. The European Patent Office(EPO), United States(US), Spain(ES), and Poland(PL) patent Office are among the top ten patent offices where Grifols is filings its patents. Among the top granted patent authorities, Grifols has 22% of its grants in Spain(ES), 15% in European Patent Office(EPO) and 15% in Poland(PL).
Roche could be the strongest competitor for Grifols
Patents related to rare diseases and Covid-19 lead Grifols's portfolio
Grifols has the highest number of patents in rare diseases followed by, Covid-19 and addiction. For rare diseases, nearly 44% of patents were filed and 36% of patents were granted in Q2 2024.
Ageing related patents lead Grifols portfolio followed by cognitive disorders, and packaging
Grifols has highest number of patents in ageing followed by cognitive disorders, packaging, stroke, and hypoxia. For ageing, nearly 5% of patents were filed and 5% of patents were granted in Q2 2024.
For comprehensive analysis of Grifols's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.